Evidence map›Paper›PMID 25500583›Full record

ArticlePloS one2014

Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients.

Lucy Baldeón R, Karin Weigelt, Harm de Wit, Behiye Ozcan, Adri van Oudenaren, Fernando Sempértegui, Eric Sijbrands, Laura Grosse, Wilma Freire, Hemmo A Drexhage and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2017
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Diabetic Retinopathy and Cardiovascular Disease: A Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Lucy Baldeón RDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Immunology, Central University of Ecuador, Quito, Ecuador.
Karin WeigeltDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Harm de WitDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Behiye OzcanDepartment of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Adri van OudenarenDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Fernando SempérteguiDepartment of Immunology, Central University of Ecuador, Quito, Ecuador.
Eric SijbrandsDepartment of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Laura GrosseDepartment of Psychiatry, University of Münster, Münster, Germany.
Wilma FreireInstitute of Research in Health and Nutrition, University San Francisco de Quito, Quito, Ecuador.
Hemmo A DrexhageDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Prometeo Program SENESCYT, Central University of Ecuador and Universidad de las Fuerzas Armadas, Quito, Ecuador.
Pieter J M LeenenDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLCentral University of Ecuador · ECSecretaría de Educación Superior, Ciencia, Tecnología e Innovación · ECUniversidad San Francisco de Quito · ECUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is increasing evidence that chronic inflammation is an important determinant in insulin resistance and in the pathogenesis of type 2 diabetes (T2D). MicroRNAs constitute a newly discovered system of cell regulation and in particular two microRNAs (miR-146a and miR-155) have been described as regulators and biomarkers of inflammation.

aimTo determine a putative association between the levels of miR-146a and miR-155 in serum of T2D patients, clinical parameters and serological indicators of inflammation.

methodsWe performed quantitative Real Time PCR (qPCR) of microRNAs from serum (56 Ecuadorian T2D ambulatory patients and 40 non-diabetic controls). In addition, we evaluated T2D-related serum cytokines.chemokines and growth factors using a commercially available multi-analyte cytometric bead array system. We correlated outcomes to clinical parameters, including BMI, HbA1c and lipid state.

resultsThe Ecuadorian non-diabetic controls appeared as overweight (BMI>25: patients 85%, controls 82.5%) and as dyslipidemic (hypercholesterolemia: patients 60.7%, controls 67.5%) as the patients. The serum levels of miR-146a were significantly reduced in T2D patients as compared to these non-diabetic, but obese/dyslipidemic control group (mean patients 0.61, mean controls set at 1; p = 0.042), those of miR-155 were normal.The serum levels of both microRNAs correlated to each other (r = 0.478; p<0.001) and to leptin levels. The microRNAs did not correlate to BMI, glycemia and dyslipidemia.From the tested cytokines, chemokines and growth factors, we found IL-8 and HGF significantly raised in T2D patients versus non-diabetic controls (p = 0.011 and 0.023 respectively).

conclusionsThis study shows decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the background of obesity and dyslipidemia.

Indexed as

AdultBiomarkersCase-Control StudiesChronic DiseaseCytokinesDiabetes Mellitus, Type 2FemaleHumansInflammationIntercellular Signaling Peptides and ProteinsLipidsMaleMicroRNAsReal-Time Polymerase Chain ReactionBiomarkersCytokinesIntercellular Signaling Peptides and ProteinsLipidsMicroRNAsMIRN146 microRNA, humanMIRN155 microRNA, human

Identifiers

PMID25500583
PMCPMC4264887
OpenAlexW2034586402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.